Quick Facts

• Approved use: Prescription medication for supporting the management of anxiety disorders.
• Therapeutic objective: Intended to help control symptoms related to anxiety, such as panic attacks.
• Role: Utilized as an option in a comprehensive treatment plan for certain psychological and neurological conditions.

---

Clonafit BETA is a combination prescription medication containing two active components: clonazepam and propranolol. The primary goal of treatment with this combination is to support the management of certain anxiety disorders, including those associated with panic attacks. Clonazepam, which acts on the central nervous system, helps to reduce excessive nerve activity in the brain. Propranolol may help to moderate physical symptoms often associated with anxiety, such as a rapid heart rate or tremor, by affecting the body's response to certain natural substances. This dual approach aims to address both the neurological and physical manifestations of the condition.

Clonafit BETA may be prescribed for individuals with anxiety disorders when a healthcare professional determines this combination is an appropriate part of their overall care strategy. This medication is also sometimes utilized in the treatment of specific seizure disorders (epilepsy) and tremor, depending on the prescribing guidance. Do not discontinue this medication without consulting a qualified medical professional.

Regulatory References

1. NIH MedlinePlus guidance

Who Can and Cannot Use Clonafit BETA? — Official Eligibility Rules

The eligibility profile for Clonafit BETA, a fixed-dose combination of Clonazepam and Propranolol, is strictly defined by regulatory documents, encompassing absolute contraindications and specific population restrictions.

---

Contraindications and Restrictions

Classification	Population or Condition	Regulatory Status
Absolute Contraindications	Severe respiratory diseases (e.g., bronchial asthma, severe COPD), cardiogenic shock, decompensated heart failure, second- or third-degree AV block, acute narrow-angle glaucoma, and known hypersensitivity to either component.	Prohibited
Age and Development	Children and adolescents under 18 years; Pregnant or lactating individuals.	Not Recommended
Condition-Specific	Severe hepatic impairment; patients with a history of alcohol or substance dependence.	Restricted Use

---

Age-Group Eligibility

Adults (18–65 years) represent the primary eligible population, provided no contraindications are present. Use in older adults (65 years) is permitted only with caution and close monitoring due to increased sensitivity to both the central nervous system (Clonazepam) and cardiovascular (Propranolol) effects. The safety and efficacy for the anxiety indication are not established in the pediatric population. These rules establish clear boundaries based on a patient's underlying physiological status and official regulatory data.

Interactions with other medicines and products

Interaction Scope

Category	Official Regulatory Information
Medicinal product categories with documented interactions:	CNS Depressants (Opioids, Sedatives, Antihistamines); CYP Enzyme Modulators; Non-dihydropyridine Calcium Channel Blockers; NSAIDs; Alcohol.
Mechanistic basis of interactions:	Pharmacodynamic Reinforcement (additive CNS/cardiac effects); Pharmacokinetic Modulation (CYP Inhibition/Induction); Reduced Oral Bioavailability.
Timing-based interaction rules:	Administration with Calcium Salts or Multivitamins should be separated by at least 2 hours.
Interaction-related restrictions:	Contraindicated co-administration with Opioids and Non-dihydropyridine Calcium Channel Blockers.

Interaction Classifications (High-Level)

Classification	Official Regulatory Information
Interaction severity classification:	Contraindicated Combinations; Clinically Significant Pharmacokinetic Interactions; Clinically Significant Pharmacodynamic Interactions.
Interaction-context constraints:	Contraindicated for the Clonazepam component in patients with clinical evidence of significant liver disease.

Official Interaction Statements

• Co-administration with Opioids is restricted due to the combined risk of profound sedation and respiratory depression from the Clonazepam component.
• Non-dihydropyridine Calcium Channel Blockers (e.g., Verapamil, Diltiazem) are contraindicated with the Propranolol component due to the risk of additive bradycardia and hypotension.
• CYP enzyme inhibitors (e.g., Cimetidine, Fluoxetine) increase the systemic exposure of Propranolol, while inducers (e.g., Phenytoin) decrease the plasma levels of both active components.
• Alcohol (Ethanol) contributes to additive central nervous system depression and may also alter Propranolol plasma levels.
• The Propranolol component may reduce patient responsiveness to typical doses of Epinephrine in the event of a severe anaphylactic reaction.

Connection to the overall interaction profile: Regulatory documents define the product's interaction structure through synergistic risks of CNS and cardiovascular depression, enforced by formal contraindications. The profile also mandates caution for agents that alter the drug's metabolic clearance via CYP enzymes and imposes administration timing constraints for non-metabolic binding agents.

Clonafit BETA comprises two distinct active molecular entities. The first component, a benzodiazepine, functions as a positive allosteric modulator of the gamma-aminobutyric acid type A (GABAA) receptor complex throughout the central nervous system. This interaction facilitates the binding and enhances the intrinsic action of the inhibitory neurotransmitter GABA. The downstream consequence is an increased frequency of chloride ion channel opening, resulting in an enhanced influx of Cl^- ions, which hyperpolarizes the postsynaptic neuron membrane. This decreased neuronal excitability culminates in generalized inhibitory effects within the central nervous system.

The second component, a non-selective beta-adrenergic receptor antagonist, acts by competitively inhibiting the binding of endogenous catecholamines (e.g., epinephrine and norepinephrine) at both beta1 and beta2 receptors. Within myocardial tissue, beta1 antagonism reduces cyclic AMP synthesis and subsequently decreases intracellular calcium flux, leading to reduced cardiac chronotropy and inotropy. Systemically, the combined beta-blockade modulates sympathetic outflow to the cardiovascular system, resulting in a reduction of peripheral vascular resistance and systemic arterial pressure.

How to Use Clonafit BETA: Official Administration Guidelines

This information describes the official instructions for administering Clonafit BETA (a fixed-dose combination of Clonazepam and Propranolol).

---

Administration Scope

Instruction Area	Requirement
Route of Administration	Oral (by mouth)
Dosage Schedule	Dosing must be individualized by a physician, starting at the lowest effective dose, and gradually titrated upward based on patient response. Specific combination strengths are available.
Timing with Meals	The tablet may generally be taken with or without food.
Age-Group Rules	Older patients (elderly) must be started on a low dose and closely monitored due to increased risk of central nervous system depression.
Missed Dose	If a dose is missed, it should be taken as soon as remembered unless it is near the time for the next scheduled dose. Do not double the dose.

---

Procedural Requirements

Official Step Sequence:

1. The patient initiates treatment on the lowest prescribed dose as determined by the physician.
2. The patient takes the fixed-dose combination tablet orally, swallowing it whole with water, typically at consistent times each day.
3. The dose is maintained or adjusted by the doctor over time based on continued patient assessment.
4. When the treatment is concluded, the medicine must be gradually reduced (tapered) under medical supervision to prevent severe withdrawal effects.

Special Procedural Conditions:

• The tablet must be swallowed whole and must not be crushed, chewed, or broken.
• Abrupt discontinuation is prohibited. A medically supervised dose taper is mandatory for all patients stopping the medicine.

---

Connection to the Overall Use Protocol: The official administration guidelines establish that the proper use of Clonafit BETA relies entirely on an individualized, titrated dosing protocol overseen by a physician. These guidelines mandate the specific oral route and swallowing the tablet whole to ensure the stability of the combination drug's release profile. The instructions' most critical procedural requirement is the necessity of a gradual dose taper upon cessation of treatment, which is non-negotiable.

Research Evidence Overview

The research that has been conducted for the fixed-dose combination of Clonazepam and Propranolol (Clonafit BETA) has primarily focused on adults with anxiety disorders. This section details the types of studies that have been conducted, the specific outcomes that studies monitored, and the limitations and uncertainty that remains in the current body of evidence. The available research mostly involves short-term observation periods, and research is ongoing to provide more context regarding its use.

Evidence for Management of Anxiety Disorders

The primary evidence base for this combination comes from randomized controlled trials (RCTs). These are formal studies conducted during periods of increased symptom activity where participants were carefully assigned to different treatment groups for comparison. Research examined adult patients who had a diagnosis of an anxiety disorder and were experiencing moderate-to-severe symptoms at the start of the study. These trials were designed to explore how outcomes related to physical discomfort and outcomes reflecting daily functioning were observed over defined, short time intervals. Findings describe patterns observed in the studies over these periods.

What Researchers Examined in Trials

In these research settings, studies monitored changes using standardized assessment instruments. For instance, the Hamilton Rating Scale for Anxiety (HAM-A) is a tool used in research exploring how symptoms change over time. Additionally, the Clinical Global Impressions (CGI) scales were applied in studies examining patient-reported experiences to document the clinician's and patient's perspective on the overall clinical status and any changes that were monitored during the trial. Studies report how symptoms evolved in the specific observed populations during the short duration of the research.

Data on Extended Use and Follow-Up Duration

The follow-up durations were limited in the main clinical trials conducted for the Clonafit BETA combination. Most evidence was observed in some studies over an approximately 8-week period. Therefore, while research provides insight into short-term changes, long-term effects are not fully established. Information is insufficient to fully characterize the durability of the patterns observed in the studies or how patients may experience the combination beyond the short follow-up period. The follow-up durations were limited, and certainty remains low regarding outcomes after the initial treatment interval.

Areas of Research Uncertainty and Gaps

A key limitation of the existing research is the limited information for long-term outcomes and extended safety monitoring. The sample sizes were modest in some of the original studies, which may affect the generalizability of the findings describing group patterns. Furthermore, comparative evidence is lacking between this specific fixed-dose combination and other existing treatment approaches. The results apply only to the populations studied and under the specific conditions of the trial, meaning research provides context but not individual predictions for all patients. Existing studies provide limited insight into how symptoms might change outside of the defined, short study window.

Key Studies & References Efficacy, Safety and Tolerability of Clonazepam 0.25 mg and Propranolol 10/20 mg Fixed-dose Combination among Anxiety Disorder Patients: A Randomized, Double-blind, Multicentric, Active-controlled, Phase IV Study

Common questions about Clonafit BETA (FAQ)

---

Q: Is Clonafit BETA a narcotic or addictive substance?

A: The official classification states that the Clonazepam component is designated as a Schedule IV controlled substance by regulatory bodies, such as the U.S. Drug Enforcement Administration (DEA). This classification is used for medicines with a potential for abuse and dependence. The specific term 'narcotic' typically refers to opioid drugs and does not apply to this classification.

---

Q: How long does the effect of a dose of Clonafit BETA last?

A: The duration of the medication's effects is related to the characteristics of its active components. Official pharmacokinetics data for the Clonazepam component suggest that the primary effects may last for approximately 8 to 12 hours in adults. However, the medicine takes significantly longer to be fully eliminated from the body.

---

Q: Is Clonafit BETA the same as Clonafit?

A: No, Clonafit BETA is described in official product labeling as a fixed-dose combination product that contains two active ingredients: Clonazepam and Propranolol. If the term 'Clonafit' refers to the single-ingredient Clonazepam product, then the combination product is different because it includes the additional beta-blocker component (Propranolol).

---

Q: What is the 'BETA' part of the name referring to?

A: The 'BETA' in the name refers to the second active ingredient, Propranolol, which belongs to the class of medications known as beta-blockers (a non-selective beta-adrenergic receptor antagonist). The combination product contains one drug from the benzodiazepine class and one drug from the beta-blocker class.

---

Q: Can Clonafit BETA cause weight gain or weight loss?

A: Official information from regulatory documents indicates that weight changes (either gain or loss) have been reported as adverse reactions for the component drugs. However, weight change is not consistently listed as a common adverse reaction in official classifications.

---

Q: Can Clonafit BETA affect a person's ability to drive?

A: Official warnings state that side effects such as drowsiness, dizziness, and problems with coordination are possible with this medicine. Due to these potential central nervous system effects, caution is advised regarding activities that require full mental alertness, such as driving or operating machinery.

---

Q: Is Clonafit BETA an antidepressant?

A: No, Clonafit BETA is a combination of a benzodiazepine (Clonazepam) and a beta-blocker (Propranolol). The active components are not formally classified as antidepressants. While the medication may be used in managing conditions alongside antidepressants, it does not belong to the antidepressant drug class.

---

Q: Is the research on Clonafit BETA still ongoing?

A: Official regulatory processes require continued monitoring and data collection after a product is approved to assess its long-term safety and effects. This post-marketing surveillance means that data related to the drug is subject to ongoing collection and monitoring as required by regulatory bodies.

---

Q: Does Clonafit BETA affect blood pressure?

A: Yes, the Propranolol component is a beta-blocker that functions to reduce heart rate and blood pressure. Official warnings highlight the potential for additive effects in lowering blood pressure when this medicine is used alongside other certain drugs or in patients who already have low blood pressure.

---

Q: Are there any common foods or drinks that interact with Clonafit BETA?

A: Regulatory guidance notes the drug may be taken with or without food. However, official labeling sometimes advises caution regarding the consumption of grapefruit products, as they may potentially affect the body's processing of the active ingredients. Information regarding alcohol is provided in the official interaction warnings.

---

Q: Does Clonafit BETA make you feel drowsy or tired?

A: Yes, regulatory documents indicate that feelings of drowsiness (somnolence), fatigue, and tiredness are among the commonly reported side effects of both component drugs. These feelings may be particularly noticeable during the initial period of taking the medicine.

---

Q: Is it normal to feel a change in mood after starting Clonafit BETA?

A: Official product information advises monitoring for a possible association with unusual thoughts or behaviors, including changes in mood, worsening of pre-existing depression, and confusion. Patients and caregivers are advised to observe for any such effects.

---

Q: Can Clonafit BETA be taken if a person has kidney problems?

A: Official information generally advises that this medicine should be used with caution in patients with pre-existing kidney disease. Kidney impairment can slow the body's clearance of the medicine, which may increase the effects of the active components.

---

Q: Has there been much research published on the long-term use of Clonafit BETA?

A: Regulatory summaries confirm that the main clinical trials for the fixed-dose combination product involved short-term observation periods, typically around 8 weeks. As a result, the available evidence is considered limited, and the long-term effects and safety profile are not fully established.

---

Q: Can Clonafit BETA cause dependence if taken regularly?

A: Official warnings, including FDA Boxed Warnings, state that the risk of dependence, abuse, and addiction is associated with the Clonazepam component. This risk increases with a longer duration of use, which includes regular long-term treatment.

---

Q: What are the eligibility criteria for being prescribed Clonafit BETA?

A: Regulatory documents define the specific approved uses (indications) and the contraindicating conditions for the medication. Eligibility for use is based on meeting the approved indications while avoiding known safety restrictions.

---

Q: Does Clonafit BETA have a generic version available?

A: While generic versions of the individual active components (Clonazepam and Propranolol) are widely available, the official regulatory status for the specific fixed-dose combination product determines if an approved generic equivalent is available. This information is confirmed via official registries like the FDA's Orange Book.

---

Q: Is Clonafit BETA prescribed for pediatric patients?

A: The Clonazepam component is approved for certain uses in pediatric patients. However, the specific fixed-dose combination product may have different official age restrictions. Warnings are also in place for children regarding the Propranolol component, noting a specific risk of hypoglycemia (low blood sugar).

---

Q: Does the time of day a person takes Clonafit BETA matter?

A: Official administration guidelines emphasize the need to take the tablet at consistent times each day. This procedural requirement helps to ensure steady concentrations of the medicine in the body, which is important for the desired therapeutic effect.

---

Q: Can Clonafit BETA be taken while breastfeeding?

A: Regulatory labeling states that both Clonazepam and Propranolol are known to pass into human breast milk. The labeling notes that a decision must be made regarding whether to discontinue nursing or discontinue the drug, taking into account the drug's importance to the patient.

---

Q: Does Clonafit BETA affect fertility?

A: Regulatory sources have provided no conclusive evidence from official human studies to confirm that the Clonazepam component negatively affects fertility in men or women. Official data concerning fertility for the Propranolol component is also not consistently conclusive across human studies.

---

Q: Is it possible to develop a tolerance to Clonafit BETA?

A: Official warnings concerning physical dependence and the mandatory need for dose tapering strongly suggest that the body can develop physiological adaptations to the Clonazepam component over time. This adaptive process is related to the development of tolerance.

---

Q: What are the signs of an allergic reaction to Clonafit BETA?

A: Official documentation advises that signs of a potential allergic reaction may include rash, hives, itching, or swelling of the face, lips, tongue, or throat. These symptoms are officially listed as signs of hypersensitivity that require immediate attention.

---

Q: Is Clonafit BETA commonly prescribed for migraines?

A: The Propranolol component is officially approved for and used in the prevention of migraine headaches. However, the fixed-dose combination product may only be formally indicated (approved) for other specific conditions, such as certain anxiety disorders.

Storage and Security Requirements

Clonafit BETA (Clonazepam and Propranolol) tablets must be stored according to specific regulatory requirements to maintain product stability and ensure security, as Clonazepam is classified as a controlled substance.

Condition	Requirement
Temperature	Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with permitted brief fluctuations up to 30 C (86 F).
Protection	Keep the medicine in its original container, tightly closed, and protect it from excessive heat, moisture, and light.
Security	Store the medicine in a safe, secure place and out of the sight and reach of children to prevent misuse and accidental ingestion.

Disposal Instructions

To dispose of unused or expired Clonafit BETA, follow local regulations for controlled substances. Patients are advised to use a formal drug take-back program when available. The tablets must not be flushed down the toilet or poured into a drain.